secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2026-01-06T23:59:59+00:00
Accession:  0001104659-26-001076
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris ATI-052 Phase 1a shows favorable safety, 26-day half-life, near-complete target inhibition at low doses
--------------------------------------------------------------------------------

- ATI-052 well tolerated up to 720 mg; no serious AEs, no discontinuations, mild injection site redness.
- PK profile shows at least 26-day effective half-life with dose-proportional Cmax and AUC.
- At 30 mg, robust concentration-dependent inhibition of IL-4 and TSLP stimulated CCL17/TARC.
- Data supports potential for up to every-3-month dosing; Phase 1b in AD and asthma to start Q1 2026.
- Phase 2b in atopic dermatitis planned for H2 2026; top-line data from Phase 1b expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/0001104659-26-001076-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000110465926001076/acrs-20260106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-001076

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer